Vol. 25/No. 13

John Strickler, MD, details the latest data on the novel c-Met–targeted ADC telisotuzumab adizutecan and how the agent could affect the treatment of CRC.

John L. Marshall, MD, details updates with ctDNA in colorectal cancer, and how precision medicine with ctDNA could change the way patients are treated.

Investigators are examining and implementing several innovations that they hope will combat the persistent issue of limited access to cancer care for patients living in rural areas.

A panel of experts detail updated data and developments in the advanced renal cell carcinoma space with immunotherapy-based combination regimens.

The speed at which new drugs, combinations, and novel approaches are being introduced into routine practice presents a challenge for treating oncologists